A first proof-of-concept trial utilizing [68Ga]Ga-ABY-025 PET/CT, including 10 previously biopsy-verified HER2-low breast cancer patients, was conducted as part of the NCT05619016 basket imaging trial for patients with HER2-expressing tumors. The gene discussed is ERBB2; the disease is breast cancer.